Johanna N. H. Timmer-Bonte
Department of Medical Oncology
Radboud University Nijmegen Medical Centre
Nijmegen
Netherlands
Name/email consistency: high
- Prophylactic G-CSF and antibiotics enable a significant dose-escalation of triplet-chemotherapy in non-small cell lung cancer. Timmer-Bonte, J.N., Punt, C.J., vd Heijden, H.F., van Die, C.E., Bussink, J., Beijnen, J.H., Huitema, A.D., Tjan-Heijnen, V.C. Lung. Cancer (2008)
- Modeling the cost effectiveness of secondary febrile neutropenia prophylaxis during standard-dose chemotherapy. Timmer-Bonte, J.N., Adang, E.M., Termeer, E., Severens, J.L., Tjan-Heijnen, V.C. J. Clin. Oncol. (2008)
- Cost-effectiveness of adding granulocyte colony-stimulating factor to primary prophylaxis with antibiotics in small-cell lung cancer. Timmer-Bonte, J.N., Adang, E.M., Smit, H.J., Biesma, B., Wilschut, F.A., Bootsma, G.P., de Boo, T.M., Tjan-Heijnen, V.C. J. Clin. Oncol. (2006)
- Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors. Timmer-Bonte, J.N., Tjan-Heijnen, V.C. Anticancer. Drugs (2006)
- Timely withdrawal of G-CSF reduces the occurrence of thrombocytopenia during dose-dense chemotherapy. Timmer-Bonte, J.N., de Mulder, P.H., Peer, P.G., Beex, L.V., Tjan-Heijnen, V.C. Breast Cancer Res. Treat. (2005)
- Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study. Timmer-Bonte, J.N., de Boo, T.M., Smit, H.J., Biesma, B., Wilschut, F.A., Cheragwandi, S.A., Termeer, A., Hensing, C.A., Akkermans, J., Adang, E.M., Bootsma, G.P., Tjan-Heijnen, V.C. J. Clin. Oncol. (2005)
